Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market: Rise in research and development of novel drugs to drive the market

Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market: Introduction

  • Progressive familial intrahepatic cholestasis (PFIC) type 2 is a heterogeneous group of autosomal recessive disorder that occurs during childhood and disturbs the bile formation. This disorders is present with cholestasis at the hepatocellular origin. Major clinical manifestations involve pruritus, cholestasis, and jaundice. Patients suffering from progressive familial intrahepatic cholestasis (PFIC) type 2 usually develop fibrosis along with end-stage liver disease before adulthood.
  • The Progressive Familial Intrahepatic Cholestasis Type 2 treatment market can be segmented based on drug type, distribution channels, end-user, and region. Based on drug type, the market can be categorized into cholestyramine, ursodeoxycholic acid, rifampicin & others. Based on end-user, the market can be split into hospitals, specialty clinics, ambulatory surgical centers, and others. In terms of distribution channel, the Progressive Familial Intrahepatic Cholestasis Type 2 treatment market can be classified into hospital pharmacies, retail pharmacies, and ecommerce.

 Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81662

Opportunities of Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market

  • Rise in research and development of novel drugs for progressive familial intrahepatic cholestasis (PFIC) type 2 treatment is projected to boost the market during the forecast period. For instance, in August 2020, Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel therapies for debilitating liver diseases, presented an overview from its phase 2 indigo study at the International Liver Congress 2020. The five-year analysis represented that patients with Progressive familial intrahepatic cholestasis (PFIC) type 2, also called as bile salt export pump (BSEP) deficiency, who achieved long-term maralixibat treatment have a significant enhancement in the transplant-free survival.
  • Increase in drug approvals from regulatory bodies is anticipated to fuel the global progressive familial intrahepatic cholestasis type 2 treatment market during the forecast period. For instance, in November 2020, Mirum Pharmaceuticals, Inc., announced that the company’s Marketing Authorization Application (MAA) for its investigational medicine, Maralixibat, for the treatment of patients with progressive familial intrahepatic cholestasis type 2 (PFIC2), received approval for review from the European Medicines Agency (EMA).
  • Progressive familial intrahepatic cholestasis (PFIC) type 2 is a rare genetic disorder that has no basic treatment and requires R & D for novel treatment drugs. There is no curative treatment for Progressive familial intrahepatic cholestasis (PFIC) type 2. Hence, lack of novel therapies is anticipated to hamper the progressive familial intrahepatic cholestasis (PFIC) type 2 treatment market.

 Request for Analysis of COVID-19 Impact on Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81662

North America to Capture Major Share of Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market

  • North America region is anticipated to hold a notable share of the global progressive familial intrahepatic cholestasis type 2 treatment market during the forecast period, due to an increase in clinical trials intervention for progressive familial intrahepatic cholestasis type 2 treatment. For instance, in September 2020, Albireo Pharma, Inc. announced positive topline results from PEDFIC 1, a global Phase 3 clinical trial evaluating the safety of odevixibat conducted for PFIC1 and PFIC2. Odevixibat reduce bile acids in both PFIC1 and PFIC2 patients and demonstrated a clinically proven better results for pruritus.
  • However, the progressive familial intrahepatic cholestasis type 2 treatment market in Europe is anticipated to expand at a rapid pace during the forecast period. Additionally, key market players are focused on the development of novel drugs to broaden their product portfolio, which is anticipated to fuel the progressive familial intrahepatic cholestasis type 2 treatment market in the region during the forecast period. For instance, in December 08, 2020, Albireo Pharma, Inc. submitted Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) to obtain derive approval for odevixibat, useful for the treatment of patients suffering with progressive familial intrahepatic cholestasis (PFIC) type 2.

 Pre book Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=81662&ltype=S

Key Players Operating in Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market

The global progressive familial intrahepatic cholestasis type 2 treatment market is highly fragmented, with the presence of various key players. A large number of manufacturers hold a major share in their respective regions. Major players operating in the global progressive familial intrahepatic cholestasis type 2 treatment market are:

  • Teva Pharmaceutical Industries Ltd.
  • AbbVie, Inc.
  • Glenmark Pharmaceuticals Limited
  • Par Pharmaceuticals, Inc.
  • Mylan Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Novartis International AG
  • Akorn, Inc.
  • Albireo Pharma, Inc.
  • Mirum Pharmaceuticals

 Read More Information:  https://www.transparencymarketresearch.com/progressive-familial-intrahepatic-cholestasis-type-2-treatment-market.html

Browse More Trending Reports by Transparency Market Research:

Cranial & Auricular Electrostimulation Devices Market:

Cranial & auricular electrostimulation devices are used to treat different types of physical as well psychological conditions using electric current of varying power. These devices deliver the natural level of micro current, via small clips worn on the earlobes, through to the brain in order to stimulate and modulate specific group of nerve cells.These devices stimulate the specific acupuncture points on the ear. These devices are extensively employed and are being evaluated for the treatment of a wide range of medical conditions such as pain, insomnia, depression, anxiety, and weight loss.

Surgical Robotics Market:        

Some of the important reasons likely to foster growth of the global surgical robotics market comprise increasing usage and acceptance of minimally invasive surgeries due to several benefits. These surgeries come with shorter hospital stays. In addition, the launch of economical and versatile surgical robots by new market participants is expected to spur demand in the market. International players' rising penetration is having a beneficial influence on the growth of the growth. One of the most important aspects that support the market growth is the rising number of permissions from regulatory agencies, such as the FDA to the market players. Additional reasons contributing to this trend include the increased number of robotic surgical system, the steady development of robotic surgical technology, and the growing popularity of robotics-assisted procedures such as hysterectomies.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

Back to news